Cayman Ouabain-d3

Xaliproden is an agonist of the serotonin (5-HT) receptor subtype 5-HT_1A (IC₅₀ = 4.3 nM in a radioligand binding assay). It is selective for 5-HT_1A over 5-HT₂ and α₁-adrenergic receptors (IC₅₀s = 697 and 630 nM, respectively), as well as a panel of 13 additional neurotransmitter receptors and ion channels (IC₅₀s = ≥10 µM for all) but also binds sigma (σ) receptors (IC₅₀ = 73 nM). Xaliproden (250 nM) increases NGF-induced neurite outgrowth and α-actinin levels in PC12 cells. It decreases hippocampal neuronal damage and reduces impairments in sensorimotor function in rat models of transient global ischemia induced by four-vessel occlusion (4-VO) and sciatic nerve crush injury, respectively, when administered at a dose of 10 mg/kg per day. Xaliproden (10 mg/kg per day) inhibits CNS mononuclear cell infiltration and increases in cerebrospinal fluid IgG levels in a rat model of experimental autoimmune encephalomyelitis (EAE) induced by myelin basic protein.

WARNING This product is not for human or veterinary use.